Navigation Links
Joint distraction promotes structural repair in patients with severe knee osteoarthritis
Date:6/13/2008

Paris, France, Friday 13 June 2008: Joint distraction (the use of a surgical frame around a degenerated joint to strengthen and promote repair) promotes cartilage repair in severe end stage osteoarthritis (OA) of the knee, as demonstrated for the first time by data presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.

In the study, an external fixation frame, with springs, was used to bridge the knee joint in 19 relatively young osteoarthritis patients (<60 years). The frame was then distracted by 5mm over a period of two months with the aim of promoting knee repair by removing mechanical stress on the knee. The functional ability and pain scores of the patients were poor before treatment (40% and 30% of the maximum WOMAC score), however, following joint distraction, both scores increased to more than 80%, equivalent to almost complete normalisation in terms of symptoms experienced.

MRI and digital x-ray evaluation carried out at baseline and at one year follow up showed evidence of cartilage repair. Cartilage volume and subchondral bone covered with cartilage increased by 50% and 40% respectively and mean cartilage thickness increased from baseline to one year follow up. Biomarkers of cartilage and bone (breakdown and synthesis), measured in serum and urine, demonstrated an increased level of turnover of cartilage and bone during distraction that returned to normal in the months after treatment, with a gradual increase for cartilage synthesis markers over time indicative of structural repair due to distraction.

Professor Floris Lafeber of the University Medical Center Utrecht, The Netherlands, who led the study, said, "We are delighted to report such an impressive outcome in the use of joint distraction for severe osteoarthritis of the knee. Positive results have been sustained over the two year follow up period, suggesting the potential for joint distraction to delay the need for a joint prosthesis in these relatively young patients. Our data are very promising, demonstrating the clinical efficacy and potential for structural repair. The logical next step should be the implementation of a prolonged prospective multi-centre study on the procedure."

Pain, functional disability, clinical condition and flexion of the joint were evaluated during two years of follow-up using a box-scale, a questionnaire (slightly modified WOMAC), and by physical examination. In addition, serum and urine samples were stored for biomarker evaluation and radiographs and MRIs were taken at regular intervals.

The knee (the largest joint in the body) is a common location for osteoarthritis, which causes painful joint damage and inflammation. This happens because the, as cartilage in the knee gradually roughens and thins, surrounding bone thickens to compensate and the synovium (surrounding membrane) swells, often producing extra fluid. The capsule and ligaments slowly thicken and shrink and muscles can weaken and thin, causing the knee joint to become unstable.

Osteoarthritis of the knee is twice as common in women as in men, mainly occurring in women over the age of 50. So far, no treatment has been available and end stage placement of a joint prosthesis is often inevitable. Delaying such joint replacement surgery and preserving the original joint, specifically in the light of the ageing population, offers significant social and economical potential.


'/>"/>

Contact: Rory Berrie
eularpressoffice@uk.cohnwolfe.com
44-077-892-70392
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
2. Joint NJ/NY Rally for Addiction Recovery to Be Hub of Events Nationwide
3. Joint Juice Launches New Ready-to-Drink Glucosamine & Vitamin-Enhanced Dietary Supplement Water Nationwide
4. SAIC Selected to Support the U.S. Military Theater Medical Information Program-Joint
5. The impact of physical activity on weight-bearing knee joint
6. Joint Center Says New Approach Required to Reduce Black Infant Mortality
7. Merlyn Medical Announces FDA Approval for FlexWarmer in a Joint Agreement with Elltec and Suzuken
8. The Joint Commission Enhances Quality Check Website
9. OCS and Press Ganey Partner to Create Joint Analysis of Outcomes and Satisfaction
10. More Damage Than Good? Shock Survey Reveals Sport can Actually be bad for Your Joints
11. Delaware Court Approves Bioenvision, Genzyme Joint Petition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in ... a special report in the May issue of Consumer Reports focused on heart health. ... for results achieved during and after coronary bypass and aortic valve replacement procedures. ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... ... April 24, 2017 , ... As part of the ... to honor the victims of the Holocaust and Nazi persecution, Center for Medicine ... and Auschwitz on its CMATH Champions trip to Germany and Poland next week. , ...
(Date:4/24/2017)... ... 2017 , ... The California Dental Association Foundation’s two-day volunteer dental clinic, ... during the April 22-23 event at the San Mateo Event Center. , In ... care, CDA Cares educates the public and policymakers about the importance of good oral ...
(Date:4/24/2017)... ... April 24, 2017 , ... ALP Nutrition®, a company ... its popular products are now available for purchase on StackedNutrition.com, a popular website ... of premium natural ingredients in making all of its products. These ingredients come ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
Breaking Medicine Technology: